Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Breast Tissue Biomarkers Predicting Short Term Risk of Breast Cancer
Study Type: Screening
Phase: N/A
NCTID: NCT00291096
Principal Investigator:
Carol Fabian
Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge CDK Study
Study Type: Treatment
Phase: III
NCTID: NCT06377852
Principal Investigator:
Ryan Rader
A Phase III Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative HR+/HER2- Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
Study Type: Treatment
Phase: III
NCTID: NCT06982521
Principal Investigator:
Yiduo Hu
Ice Compress: Randomized Trial of Limb Cryocompression versus continuous Compression versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy
Study Type: Prevention
Phase: N/A
NCTID: NCT05642611
Principal Investigator:
Lauren Nye
A Phase Ib/II Trial of Zunsemetinib in Combination with Capecitabine in Patients with Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer with Bone Metastasis
Study Type: Treatment
Phase: I/II
NCTID: NCT06374459
Principal Investigator:
Qamar Khan
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
Study Type: Treatment
Phase: III
NCTID: NCT06876714
Principal Investigator:
Yiduo Hu
A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2? early breast cancer Adjuvant WIDER
Study Type: Treatment
Phase: III
NCTID: NCT05827081
Principal Investigator:
Priyanka Sharma
Phase IIA Trial of Acolbifene 20 mg vs Low Dose Tamoxifen 5 mg in Pre-menopausal Women at High Risk for Development of Breast Cancer
Study Type: Prevention
Phase: II
NCTID: NCT05941520
Principal Investigator:
Carol Fabian
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer SCARLET, A Randomized Phase III Study
Study Type: Treatment
Phase: III
NCTID: NCT05929768
Principal Investigator:
Priyanka Sharma
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
Study Type: Treatment
Phase: III
NCTID: NCT05879926
Principal Investigator:
Lauren Nye